Real-Time Monitoring of Heart Failure at Yale New Haven Health System
This study is observing patients with heart failure (when your heart can't pump enough blood to meet your body's needs) who are already being seen within the Yale New Haven Health System. It's looking at how many people are hospitalized for heart failure and the types and doses of medicines they receive over 10 years. The goal is to better understand heart failure and how well current treatments are working in a large group of patients. You can join if you are 18 or older, have a heart failure diagnosis, and are a patient within the Yale New Haven Health System. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study planning to include 40,000 participants. It uses existing electronic health records to gather information.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' health information will be monitored for 10 years to track hospitalizations and medication use.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nihar Desai, MD MPH · STUDY_DIRECTOR · Yale University
- Tariq Ahmad, MD MPH · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of participants hospitalized for heart failure10 years
Heart Failure hospitalizations
- Doses of therapies that comprise guideline directed medical therapy10 years
Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.